Coenzyme Q10 Therapy
Coenzyme Q10 Therapy
复制标题
DOI：
10.1159/000360101
复制
发表时间：
2014-01-01
影响因子：
1.1
通讯作者：
Sanchez-Alcazar, Jose A.
中科院分区：
文献类型：
--
作者：
Garrido-Maraver, Juan;Cordero, Mario D.;Sanchez-Alcazar, Jose A.
多年来，辅酶Q（10）（CoQ（10））因其在线粒体生物能量学中的关键作用而闻名;后来的研究证明其存在于其他亚细胞组分和血浆中，并广泛研究了其抗氧化作用。这两个功能构成了支持辅酶Q临床使用的基础（10）。此外，在线粒体内膜水平，辅酶Q（10）被认为是解偶联蛋白功能的强制性辅因子和线粒体过渡孔的调节剂。此外，最近的数据表明，辅酶Q（10）影响参与人类细胞信号传导，代谢和运输的基因的表达，辅酶Q（10）补充剂的一些影响可能是由于这种特性。辅酶Q（10）缺乏是由于常染色体隐性突变，线粒体疾病，衰老相关的氧化应激和致癌过程，以及他汀类药物治疗。许多神经退行性疾病、糖尿病、癌症、肌肉和心血管疾病都与低辅酶Q（10）水平以及不同的共济失调和脑肌病有关。辅酶Q（10）治疗不会对人类造成严重的不良影响，并且已经开发了新的制剂，可以增加辅酶Q（10）的吸收和组织分布。口服辅酶Q（10）是许多疾病中常见的抗氧化剂策略，可能提供显着的症状益处。(C)2014 S. Karger AG，巴塞尔
For a number of years, coenzyme Q(10) (CoQ(10)) was known for its key role in mitochondrial bioenergetics; later studies demonstrated its presence in other subcellular fractions and in blood plasma, and extensively investigated its antioxidant role. These 2 functions constitute the basis for supporting the clinical use of CoQ(10). Also, at the inner mitochondrial membrane level, CoQ(10) is recognized as an obligatory cofactor for the function of uncoupling proteins and a modulator of the mitochondrial transition pore. Furthermore, recent data indicate that CoQ(10) affects the expression of genes involved in human cell signaling, metabolism and transport, and some of the effects of CoQ(10) supplementation may be due to this property. CoQ(10) deficiencies are due to autosomal recessive mutations, mitochondrial diseases, aging-related oxidative stress and carcinogenesis processes, and also statin treatment. Many neurodegenerative disorders, diabetes, cancer, and muscular and cardiovascular diseases have been associated with low CoQ(10) levels as well as different ataxias and encephalomyopathies. CoQ(10) treatment does not cause serious adverse effects in humans and new formulations have been developed that increase CoQ(10) absorption and tissue distribution. Oral administration of CoQ(10) is a frequent antioxidant strategy in many diseases that may provide a significant symptomatic benefit. (C) 2014 S. Karger AG, Basel